Intellia Therapeutics, Inc

(NASDAQ:NTLA)

Latest On Intellia Therapeutics, Inc (NTLA):

Date/Time Type Description Signal Details
2023-05-04 14:57 ESTNewsIntellia Therapeutics GAAP EPS of -$1.17 beats by $0.21, revenue of $12.6M beats by $0.84MN/A
2023-05-04 14:57 ESTNewsIntellia Therapeutics, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-04 14:57 ESTNewsIntellia Therapeutics, Inc. (NTLA) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 14:57 ESTNewsIntellia jumps 13% after Q1 updatesN/A
2023-05-04 02:28 ESTNewsIntellia Therapeutics Q1 2023 Earnings PreviewN/A
2023-04-21 23:02 ESTNewsIntellia Therapeutics: Signs Of Possible LifeN/A
2023-04-14 00:52 ESTNewsIntellia up 12% as Canaccord starts with Buy citing gene editing approachN/A
2023-04-14 00:52 ESTNewsGene editing stocks rally as Wall Street turns bullishN/A
2023-03-21 23:26 ESTNewsIntellia wins key FDA designation for CRISPR candidateN/A
2023-03-14 23:49 ESTNewsIntellia gains as BMO upgrades citing recent weaknessN/A
2023-03-07 22:33 ESTNewsIntellia Therapeutics: Progressing Pipeline Signals Positive Outlook For InvestorsN/A
2023-03-02 19:53 ESTNewsIntellia stock rises on FDA nod to start trial of CRISPR gene editing therapyN/A
2023-02-23 17:51 ESTNewsIntellia Therapeutics GAAP EPS of -$1.40 misses by $0.04, revenue of $13.6M beats by $2.89MN/A
2023-02-23 17:51 ESTNewsIntellia, Novartis end gene editing partnership for sickle cell diseaseN/A
2023-02-23 17:51 ESTNewsIntellia Therapeutics, Inc. (NTLA) Q4 2022 Earnings Call TranscriptN/A
2023-02-22 15:55 ESTNewsIntellia Therapeutics Q4 2022 Earnings PreviewN/A
2023-02-01 19:35 ESTNewsEditas, Beam win bullish views as Cantor launches gene editing coverageN/A
2023-01-24 17:59 ESTNewsIntellia Therapeutics upgraded at Citi after recent selloffN/A
2023-01-11 12:52 ESTNewsIntellia awarded innovation passport in UK for genetic disorder treatmentN/A
2022-12-20 16:01 ESTNewsIntellia: Most Advanced In A Tough FieldN/A
2022-12-20 16:01 ESTNewsIntellia: In-Vivo Gene Editing Platform Continues To DeliverN/A
2022-12-01 15:07 ESTNewsIntellia therapeutics dips on pricing of public offering of common stockN/A
2022-11-03 13:07 ESTNewsIntellia Therapeutics GAAP EPS of -$1.49 misses by $0.21, revenue of $13.27M beats by $2.43MN/A
2022-11-03 13:06 ESTNewsIntellia Therapeutics, Inc. (NTLA) Q3 2022 Results - Earnings Call TranscriptN/A
2022-10-06 00:41 ESTNewsIntellia Therapeutics: Top Speculative Trade In The Biotech SpaceN/A
2022-09-16 13:20 ESTNewsIntellia gains after positing early data for gene-edited hereditary angioedema candidateN/A
2022-09-16 13:20 ESTNewsIntellia, Regeneron post early data to highlight gene editing in ATTR amyloidosis cardiomyopathyN/A
2022-09-16 13:19 ESTNewsIntellia falls as analysts react to CRISPR readoutsN/A
2022-09-02 02:53 ESTNewsIntellia wins FDA orphan drug designation for genome editing therapy for severe swellingN/A
2022-08-24 07:41 ESTNewsCan Intellia One-Up Alnylam In Transthyretin Amyloidosis?N/A
2022-08-04 14:36 ESTNewsIntellia Therapeutics GAAP EPS of -$1.33 misses by $0.02, revenue of $14.03M beats by $4.53MN/A
2022-08-04 14:36 ESTNewsIntellia Therapeutics down 12% following bottom line Q2 earnings missN/A
2022-08-04 14:35 ESTNewsIntellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 00:04 ESTNewsIntellia Therapeutics Q2 2022 Earnings PreviewN/A
2022-08-03 08:59 ESTNewsAlnylam drives Intellia, Ionis higher with amyloidosis data; BridgeBio slipsN/A
2022-07-30 06:35 ESTNewsIntellia Therapeutics Is Pushing CRISPR-Based Therapy Forward, Slowly But SurelyN/A
2022-07-29 02:39 ESTNewsIntellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me BearishN/A
2022-07-11 23:16 ESTNewsCathie Wood’s ARKK seeks first positive trading month after eight straight months of declinesN/A
2022-06-24 11:06 ESTNewsIntellia, Regeneron post 12-month data for gene editing therapy in ATTR amyloidosisN/A
2022-06-16 23:02 ESTNewsIntellia Therapeutics initiated at buy at BofA on lead programs, gene editing technologyN/A
2022-05-12 21:46 ESTNewsIntellia Therapeutics: Several Catalysts Expected For H2 2022N/A
2022-05-09 14:16 ESTNewsIntellia Therapeutics stocks falls for third straight session after Q1 earnings missN/A
2022-05-06 05:46 ESTNewsIntellia Therapeutics GAAP EPS of -$1.96 misses by $0.86, revenue of $11.25M beats by $2.68MN/A
2022-05-06 05:46 ESTNewsIntellia Therapuetics drops 5% following bottom line earnings miss, balloning R&D costsN/A
2022-05-06 05:46 ESTNewsIntellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-06 05:46 ESTNewsIntellia Therapeutics, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-05 06:56 ESTNewsIntellia Therapeutics Q1 2022 Earnings PreviewN/A
2022-04-28 16:59 ESTNewsIntellia wins Outperform rating at Credit Suisse on ATTR potentialN/A
2022-03-10 03:10 ESTNewsIntellia Therapeutics receives Orphan Drug Designation for CRISPR leukemia treatmentN/A
2022-03-10 03:10 ESTNewsIntellia: One Patent Ruling Turns The Industry Upside DownN/A

About Intellia Therapeutics, Inc (NTLA):

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA Quotes by TradingView

See Advanced Chart

General

  • Name Intellia Therapeutics, Inc
  • Symbol NTLA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 312
  • Fiscal Year EndDecember
  • IPO Date2016-05-06
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.intelliatx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 63.25
  • Price/Book (Most Recent Quarter) 8.42
  • Enterprise Value Revenue 66.89
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.83
  • Next Year EPS Estimate -$3.20
  • Next Quarter EPS Estimate -$0.73
  • Profit Margin -231%
  • Operating Margin -236%
  • Return on Assets -17%
  • Return on Equity -34%
  • Revenue 57.99 million
  • Earnings Per Share -$2.00
  • Revenue Per Share $1.04
  • Gross Profit -92414000
  • Quarterly Earnings Growth -39.7%
View More

Highlights

  • Market Capitalization 4.32 billion
  • EBITDA -91114000
  • PE Ratio -4.31
  • Analyst Target Price $78.46
  • Book Value Per Share $7.96
View More

Share Statistics

  • Shares Outstanding 67.73 million
  • Shares Float 64.39 million
  • % Held by Insiders 1358%
  • % Held by Institutions 85.75%
  • Shares Short 8.09 million
  • Shares Short Prior Month 8.57 million
  • Short Ratio 5.09
  • Short % of Float 16%
  • Short % of Shares Outstanding 12%
View More

Technicals

  • Beta 2.04
  • 52 Week High $92
  • 52 Week Low $11.02
  • 50 Day Moving Average 64.28
  • 200 Day Moving Average 45.31
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Intellia Therapeutics, Inc (NTLA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Intellia Therapeutics, Inc (NTLA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$6.6 million-$0.69-$0.61-12.75%
2020-09-302020-11-05$N/A-$0.47-$0.5717.11%
2020-06-302020-08-06$N/A-$0.61-$0.679.46%
2020-03-312020-05-07$N/A-$0.63-$0.47-33.11%
2019-12-312020-02-27$10.94 million-$0.57-$0.56-2.24%
2019-09-302019-10-31$10.62 million-$0.49-$0.6119.65%
2019-06-302019-08-01$11.12 million-$0.56-$0.595.02%
2019-03-312019-05-02$10.43 million-$0.49-$0.5713.85%
2018-12-312019-02-27$7.88 million-$0.43-$0.5420.8%
2018-09-302018-10-31$7.41 million-$0.53-$0.49-8.54%
2018-06-302018-08-01$7.68 million-$0.52-$0.567.47%
2018-03-312018-05-01$7.47 million-$0.51-$0.568.6%
2017-12-312018-03-14$6.67 million-$0.61-$0.45-36.77%
2017-09-302017-10-31$7.32 million-$0.44-$0.5011.11%
2017-06-302017-08-01$5.92 million-$0.45-$0.42-7.99%
2017-03-312017-05-02$6.22 million-$0.36-$0.35-2.86%
2016-12-312017-03-14$5.63 million-$0.31-$0.21-46.92%
2016-09-302016-11-01$4.87 million-$0.22-$0.21-6.28%
2016-06-302016-08-04$4.21 million-$0.19-$0.02-850%
2016-03-312016-06-03$1.78 million-$0.19-$0.193.88%

Intellia Therapeutics, Inc (NTLA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Intellia Therapeutics, Inc (NTLA) Chart:

Intellia Therapeutics, Inc (NTLA) News:

Below you will find a list of latest news for Intellia Therapeutics, Inc (NTLA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Intellia Therapeutics, Inc (NTLA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-1712.50CALL0 0228.07TRUE00
2024-05-171510.4CALL0 1181.74TRUE00
2024-05-1717.54.3CALL0 5141.3TRUE00
2024-05-17203.3CALL2 2474.67TRUE0.50.18
2024-05-1722.51.23CALL941 34467.31FALSE-0.12-0.09
2024-05-17250.4CALL213 50966.15FALSE-0.13-0.25
2024-05-17300.05CALL17 55769.24FALSE-0.05-0.5
2024-05-17350.1CALL0 3320FALSE00
2024-05-17400.05CALL4 43115.19FALSE0.050
2024-05-1712.50PUT0 00FALSE00
2024-05-17150.05PUT0 10FALSE00
2024-05-1717.50.08PUT1 4373.41FALSE-0.09-0.53
2024-05-17200.55PUT3 31563.7FALSE-0.15-0.21
2024-05-1722.51.55PUT1 21980.1TRUE-0.15-0.09
2024-05-17254PUT0 19259.04TRUE00
2024-05-17308.2PUT0 63114.27TRUE00
2024-05-173512.6PUT9 0194.62TRUE12.60
2024-05-174013.2PUT0 1200.88TRUE00
2024-06-2112.50CALL0 0158.96TRUE00
2024-06-21150CALL0 0123.88TRUE00
2024-06-2117.50CALL0 096.37TRUE00
2024-06-21200CALL0 074.17TRUE00
2024-06-2122.52.1CALL0 9963.02FALSE00
2024-06-21251.1CALL3 3764.96FALSE-0.2-0.15
2024-06-21300.3CALL7 2763.21FALSE-0.1-0.25
2024-06-2112.50PUT0 00FALSE00
2024-06-21150PUT0 085.3FALSE00
2024-06-2117.50.45PUT3 059.38FALSE0.450
2024-06-21201.6PUT0 271.58FALSE00
2024-06-2122.52.55PUT0 359.53TRUE00
2024-06-21254.23PUT0 758.73TRUE00
2024-06-21300PUT0 058.45TRUE00
2024-07-1912.50CALL0 0126.22TRUE00
2024-07-191511.5CALL0 2117.36TRUE00
2024-07-1917.55CALL0 1479.23TRUE00
2024-07-19204.1CALL0 27970.88TRUE00
2024-07-1922.52.46CALL15 3966.1FALSE0.210.09
2024-07-19251.87CALL0 7967.83FALSE00
2024-07-19300.7CALL30 60666.85FALSE-0.01-0.01
2024-07-19350.3CALL13 38367.78FALSE0.30
2024-07-19400.15CALL0 29082.42FALSE00
2024-07-19450.25CALL0 12940FALSE00
2024-07-19500.25CALL0 1410FALSE00
2024-07-1912.50.5PUT0 130FALSE00
2024-07-19150.4PUT0 3765.02FALSE00
2024-07-1917.51.25PUT0 5570.14FALSE00
2024-07-19201.8PUT0 17867.5FALSE00
2024-07-1922.53.59PUT0 101065.61TRUE00
2024-07-19254.87PUT0 32064.09TRUE00
2024-07-19308.56PUT0 49268.49TRUE00
2024-07-193512.44PUT0 8593.54TRUE00
2024-07-194013.74PUT0 3120.29TRUE00
2024-07-194523.2PUT0 0104.88TRUE00
2024-07-195027.3PUT0 0166.07TRUE00
2024-09-2012.512CALL0 1111.3TRUE00
2024-09-20157.3CALL0 472.98TRUE00
2024-09-2017.55.5CALL0 269.85TRUE00
2024-09-20204CALL1 4584.04TRUE40
2024-09-2022.54.3CALL2 3666.9FALSE0.90.26
2024-09-20252.94CALL5 10773.15FALSE0.040.01
2024-09-20301.55CALL4 120868.89FALSE-0.1-0.06
2024-09-20351.2CALL5 20176.61FALSE0.250.26
2024-09-20400.7CALL0 83672.03FALSE00
2024-09-20450.4CALL1 28273.73FALSE0.40
2024-09-20500.5CALL0 773.88FALSE00
2024-09-2012.50.4PUT0 3371.19FALSE00
2024-09-20151.05PUT0 13382.85FALSE00
2024-09-2017.51.9PUT0 5769.74FALSE00
2024-09-20202.55PUT8 21773.69FALSE2.550
2024-09-2022.54PUT2 9967.26TRUE-0.4-0.09
2024-09-20256.1PUT0 80275.11TRUE00
2024-09-20308.71PUT1 55868.26TRUE8.710
2024-09-203513PUT0 3666.35TRUE00
2024-09-204014.8PUT0 1889.39TRUE00
2024-09-204518PUT0 1092.88TRUE00
2024-09-20500PUT0 082.49TRUE00
2024-10-1812.510.14CALL0 199.35TRUE00
2024-10-181512.35CALL0 4377.02TRUE00
2024-10-1817.56.9CALL0 4765.33TRUE00
2024-10-18204.69CALL0 870.85TRUE00
2024-10-1822.53.8CALL0 777.84FALSE00
2024-10-18253.35CALL0 5975.54FALSE00
2024-10-18301.9CALL1 2469.23FALSE-0.25-0.12
2024-10-18351.25CALL0 1270.47FALSE00
2024-10-18401.05CALL0 5273.88FALSE00
2024-10-18453.46CALL0 181.41FALSE00
2024-10-18500CALL0 082.25FALSE00
2024-10-1812.50.6PUT0 1669.22FALSE00
2024-10-18151.07PUT0 668.81FALSE00
2024-10-1817.51.4PUT0 1079.02FALSE00
2024-10-18202.95PUT0 475.61FALSE00
2024-10-1822.54.7PUT0 6974.39TRUE00
2024-10-18255.6PUT0 22474.84TRUE00
2024-10-18309.1PUT19 072.37TRUE9.10
2024-10-18350PUT0 066.6TRUE00
2024-10-184015.5PUT0 474.08TRUE00
2024-10-18450PUT0 082.33TRUE00
2024-10-18500PUT0 0122.57TRUE00
2025-01-1712.510.2CALL0 32397.53TRUE00
2025-01-17159.04CALL2 2478TRUE-0.76-0.08
2025-01-1717.58.5CALL2 1477.17TRUE1.390.2
2025-01-17206.2CALL4 10572.46TRUE0.340.06
2025-01-1722.55.2CALL0 5569.45FALSE00
2025-01-17254.39CALL0 191068.53FALSE00
2025-01-17303.2CALL8 64167.25FALSE0.230.08
2025-01-17352.1CALL8 17266.82FALSE0.180.09
2025-01-17401.5CALL5 24367.17FALSE0.050.03
2025-01-17451.05CALL1 3069.51FALSE1.050
2025-01-17500.8CALL6 4970.38FALSE-0.07-0.08
2025-01-1712.51PUT0 5367.38FALSE00
2025-01-17151.78PUT0 3271.02FALSE00
2025-01-1717.52.5PUT1 968.72FALSE2.50
2025-01-17203.83PUT0 10572.99FALSE00
2025-01-1722.55.2PUT0 79666.6TRUE00
2025-01-17256.75PUT0 233967.16TRUE00
2025-01-173010.51PUT0 9466.1TRUE00
2025-01-173512.2PUT0 1565.34TRUE00
2025-01-174018PUT0 1264.49TRUE00
2025-01-17450PUT0 083.12TRUE00
2025-01-175028.8PUT0 174.34TRUE00

Latest NTLA Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST21$38.98
Jun 13, 2022 7:59 PM EST1$39
Jun 13, 2022 7:59 PM EST18$39
Jun 13, 2022 7:59 PM EST33$38.91
Jun 13, 2022 7:59 PM EST100$39

Intellia Therapeutics, Inc (NTLA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120040251/0001209191-20-040251-index.htm
2019-03-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1652130/000000000019004383/0000000000-19-004383-index.htm
2019-08-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1652130/000000000019012968/0000000000-19-012968-index.htm
2019-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000009375119000131/0000093751-19-000131-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000009375120000463/0000093751-20-000463-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000021545719006721/0000215457-19-006721-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000031506619001135/0000315066-19-001135-index.htm
2019-09-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000031506619001705/0000315066-19-001705-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000083423720005186/0000834237-20-005186-index.htm
2018-10-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924318027590/0000899243-18-027590-index.htm
2018-10-313Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924318027815/0000899243-18-027815-index.htm
2018-10-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924318027816/0000899243-18-027816-index.htm
2018-11-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924318027919/0000899243-18-027919-index.htm
2018-12-204/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924318031474/0000899243-18-031474-index.htm
2019-01-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924319001904/0000899243-19-001904-index.htm
2019-01-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924319001905/0000899243-19-001905-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924320006973/0000899243-20-006973-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924320006975/0000899243-20-006975-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924320006976/0000899243-20-006976-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924320006978/0000899243-20-006978-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924320006979/0000899243-20-006979-index.htm
2020-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000089924320021784/0000899243-20-021784-index.htm
2019-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000092542119000049/0000925421-19-000049-index.htm
2019-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000093247119005516/0000932471-19-005516-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000095010320002663/0000950103-20-002663-index.htm
2018-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000110465918041218/0001104659-18-041218-index.htm
2018-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000110465918045660/0001104659-18-045660-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000110465919006433/0001104659-19-006433-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000110465920018572/0001104659-20-018572-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000110465920021151/0001104659-20-021151-index.htm
2020-03-30SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1652130/000110465920040260/0001104659-20-040260-index.htm
2020-08-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1652130/000110465920097257/0001104659-20-097257-index.htm
2019-07-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000114036119012576/0001140361-19-012576-index.htm
2019-08-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000114036119014318/0001140361-19-014318-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000114036120002973/0001140361-20-002973-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000114420419007775/0001144204-19-007775-index.htm
2018-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312518169541/0001193125-18-169541-index.htm
2018-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312518201026/0001193125-18-201026-index.htm
2018-07-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312518222580/0001193125-18-222580-index.htm
2018-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312518233902/0001193125-18-233902-index.htm
2018-10-12S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1652130/000119312518298490/0001193125-18-298490-index.htm
2018-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312518310737/0001193125-18-310737-index.htm
2018-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312518312968/0001193125-18-312968-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312519003270/0001193125-19-003270-index.htm
2019-01-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312519015319/0001193125-19-015319-index.htm
2019-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312519052744/0001193125-19-052744-index.htm
2019-02-27POSASRPost-effective Amendment to an automatic shelf registration statementhttps://www.sec.gov/Archives/edgar/data/1652130/000119312519052893/0001193125-19-052893-index.htm
2019-02-27POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1652130/000119312519052968/0001193125-19-052968-index.htm
2019-02-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1652130/000119312519052972/0001193125-19-052972-index.htm
2019-04-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312519099432/0001193125-19-099432-index.htm
2019-04-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1652130/000119312519107874/0001193125-19-107874-index.htm
2019-05-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312519133878/0001193125-19-133878-index.htm
2019-05-0210-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1652130/000119312519135032/0001193125-19-135032-index.htm
2019-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312519154097/0001193125-19-154097-index.htm
2019-06-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1652130/000119312519165029/0001193125-19-165029-index.htm
2019-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312519209778/0001193125-19-209778-index.htm
2019-08-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1652130/000119312519228025/0001193125-19-228025-index.htm
2019-08-30S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1652130/000119312519235380/0001193125-19-235380-index.htm
2019-08-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1652130/000119312519235386/0001193125-19-235386-index.htm
2019-09-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1652130/000119312519241975/0001193125-19-241975-index.htm
2019-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312519256137/0001193125-19-256137-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312519279632/0001193125-19-279632-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312519314363/0001193125-19-314363-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312520156459/0001193125-20-156459-index.htm
2020-06-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1652130/000119312520157348/0001193125-20-157348-index.htm
2020-06-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1652130/000119312520159684/0001193125-20-159684-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312520159705/0001193125-20-159705-index.htm
2020-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000119312520263296/0001193125-20-263296-index.htm
2018-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919118031692/0001209191-18-031692-index.htm
2018-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919118031694/0001209191-18-031694-index.htm
2018-08-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919118046243/0001209191-18-046243-index.htm
2018-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919118063657/0001209191-18-063657-index.htm
2018-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919118063660/0001209191-18-063660-index.htm
2018-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919118063663/0001209191-18-063663-index.htm
2018-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919118063664/0001209191-18-063664-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919119016544/0001209191-19-016544-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919119018817/0001209191-19-018817-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919119032076/0001209191-19-032076-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919119032078/0001209191-19-032078-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919119032080/0001209191-19-032080-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919119032081/0001209191-19-032081-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919119032084/0001209191-19-032084-index.htm
2019-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919119032086/0001209191-19-032086-index.htm
2019-05-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919119033187/0001209191-19-033187-index.htm
2019-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919119034240/0001209191-19-034240-index.htm
2019-08-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919119044238/0001209191-19-044238-index.htm
2020-05-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120027162/0001209191-20-027162-index.htm
2020-05-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120027165/0001209191-20-027165-index.htm
2020-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120032648/0001209191-20-032648-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120034724/0001209191-20-034724-index.htm
2020-06-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120037647/0001209191-20-037647-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120037961/0001209191-20-037961-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120037964/0001209191-20-037964-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120037967/0001209191-20-037967-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120037970/0001209191-20-037970-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120037971/0001209191-20-037971-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120037992/0001209191-20-037992-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120040251/0001209191-20-040251-index.htm
2020-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120042820/0001209191-20-042820-index.htm
2020-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120047713/0001209191-20-047713-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120049379/0001209191-20-049379-index.htm
2020-09-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120050945/0001209191-20-050945-index.htm
2020-10-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120053567/0001209191-20-053567-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120053583/0001209191-20-053583-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120054440/0001209191-20-054440-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120055196/0001209191-20-055196-index.htm
2020-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120057297/0001209191-20-057297-index.htm
2020-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1652130/000120919120057300/0001209191-20-057300-index.htm
2019-07-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000121465919004547/0001214659-19-004547-index.htm
2019-08-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000121465919005075/0001214659-19-005075-index.htm
2018-08-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1652130/000156459018018256/0001564590-18-018256-index.htm
2018-10-3110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1652130/000156459018025733/0001564590-18-025733-index.htm
2018-12-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000156459018030544/0001564590-18-030544-index.htm
2019-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1652130/000156459019004680/0001564590-19-004680-index.htm
2019-05-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1652130/000156459019015384/0001564590-19-015384-index.htm
2019-08-0110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1652130/000156459019028042/0001564590-19-028042-index.htm
2019-10-3110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1652130/000156459019039199/0001564590-19-039199-index.htm
2020-01-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000156459020000550/0001564590-20-000550-index.htm
2020-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000156459020007032/0001564590-20-007032-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1652130/000156459020007409/0001564590-20-007409-index.htm
2020-02-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1652130/000156459020007444/0001564590-20-007444-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000156459020010859/0001564590-20-010859-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000156459020012963/0001564590-20-012963-index.htm
2020-04-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000156459020016142/0001564590-20-016142-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1652130/000156459020018482/0001564590-20-018482-index.htm
2020-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1652130/000156459020018497/0001564590-20-018497-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000156459020022377/0001564590-20-022377-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1652130/000156459020022919/0001564590-20-022919-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000156459020029961/0001564590-20-029961-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000156459020037260/0001564590-20-037260-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1652130/000156459020037798/0001564590-20-037798-index.htm
2020-10-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000156459020046696/0001564590-20-046696-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1652130/000156459020050887/0001564590-20-050887-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1652130/000156459020050915/0001564590-20-050915-index.htm
2019-01-16SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000165495419000534/0001654954-19-000534-index.htm
2019-03-25SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1652130/000165495419003213/0001654954-19-003213-index.htm
2019-06-06EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1652130/999999999519001290/9999999995-19-001290-index.htm
2019-09-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1652130/999999999519002079/9999999995-19-002079-index.htm
2019-03-11CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1652130/999999999719000954/9999999997-19-000954-index.htm
2019-05-09CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1652130/999999999719004137/9999999997-19-004137-index.htm
2020-09-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1652130/999999999720004558/9999999997-20-004558-index.htm

Intellia Therapeutics, Inc (NTLA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Intellia Therapeutics, Inc (NTLA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1358%
Institutional Ownership: 8575%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-06-19JEAN FRANCOIS FORMELADirectorSell1,400.0028.3939,746.000.00https://www.sec.gov/Archives/edgar/data/1652130/000110465918041218/0001104659-18-041218-index.htm
2018-07-16JEAN FRANCOIS FORMELADirectorSell1,402.0031.9344,762.360.00https://www.sec.gov/Archives/edgar/data/1652130/000110465918045660/0001104659-18-045660-index.htm
2019-03-01Fred E CohenDirectorBuy10,000.0016.89168,936.0010,000.00https://www.sec.gov/Archives/edgar/data/1652130/000120919119016544/0001209191-19-016544-index.htm
2018-06-19JEAN FRANCOIS FORMELADirectorSell5,286.0027.84147,162.241,400.00https://www.sec.gov/Archives/edgar/data/1652130/000110465918041218/0001104659-18-041218-index.htm
2018-07-16JEAN FRANCOIS FORMELADirectorSell5,284.0030.97163,634.911,402.00https://www.sec.gov/Archives/edgar/data/1652130/000110465918045660/0001104659-18-045660-index.htm
2020-06-16Jose E RiveraEVP, General CounselSell5,615.0021.00117,915.0022,282.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120037647/0001209191-20-037647-index.htm
2020-07-15Jose E RiveraEVP, General CounselSell5,615.0022.70127,460.5027,524.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120042820/0001209191-20-042820-index.htm
2020-06-16Jose E RiveraEVP, General CounselBuy10,000.006.8368,300.0027,897.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120037647/0001209191-20-037647-index.htm
2020-05-26Jose E RiveraEVP, General CounselSell5,615.0021.21119,094.15280,107.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120032648/0001209191-20-032648-index.htm
2020-05-26Jose E RiveraEVP, General CounselBuy10,000.006.8368,300.00285,722.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120032648/0001209191-20-032648-index.htm
2020-08-18Jose E RiveraEVP, General CounselSell5,615.0021.00117,915.0031,909.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120047713/0001209191-20-047713-index.htm
2019-03-06ANDREW SCHIERMEIEREVP, Dev and Corp StrategyBuy3,250.0016.0052,000.003,250.00https://www.sec.gov/Archives/edgar/data/1652130/000120919119018817/0001209191-19-018817-index.htm
2020-07-15Jose E RiveraEVP, General CounselBuy10,000.006.8368,300.0033,139.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120042820/0001209191-20-042820-index.htm
2020-09-15Jose E RiveraEVP, General CounselSell5,615.0021.04118,139.6036,294.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120050945/0001209191-20-050945-index.htm
2020-08-18Jose E RiveraEVP, General CounselBuy10,000.006.8368,300.0037,524.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120047713/0001209191-20-047713-index.htm
2020-10-15Jose E RiveraEVP, General CounselSell156.0024.553,829.8040,679.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120055196/0001209191-20-055196-index.htm
2020-10-15Jose E RiveraEVP, General CounselSell5,459.0024.19132,053.2140,835.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120055196/0001209191-20-055196-index.htm
2020-09-15Jose E RiveraEVP, General CounselBuy10,000.006.8368,300.0041,909.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120050945/0001209191-20-050945-index.htm
2020-11-04Jose E RiveraEVP, General CounselSell3,364.0028.0094,192.0042,315.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120057300/0001209191-20-057300-index.htm
2020-11-04Jose E RiveraEVP, General CounselBuy5,000.0013.8869,400.0045,679.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120057300/0001209191-20-057300-index.htm
2020-10-15Jose E RiveraEVP, General CounselBuy10,000.006.8368,300.0046,294.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120055196/0001209191-20-055196-index.htm
2020-10-07JOHN M LEONARDPresident and CEOSell5,000.0021.83109,150.00467,352.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120054440/0001209191-20-054440-index.htm
2020-11-04JOHN M LEONARDPresident and CEOSell50,000.0026.001,300,000.00467,352.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120057297/0001209191-20-057297-index.htm
2020-06-03JOHN M. LEONARDPresident and CEOSell5,000.0021.83109,150.00467,352.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120034724/0001209191-20-034724-index.htm
2020-07-01JOHN M. LEONARDPresident and CEOSell5,000.0021.83109,150.00467,352.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120040251/0001209191-20-040251-index.htm
2020-08-06JOHN M. LEONARDPresident and CEOSell5,000.0021.83109,150.00467,352.00https://www.sec.gov/Archives/edgar/data/1652130/000089924320021784/0000899243-20-021784-index.htm
2020-09-01JOHN M. LEONARDPresident and CEOSell5,000.0021.83109,150.00467,352.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120049379/0001209191-20-049379-index.htm
2020-10-07JOHN M LEONARDPresident and CEOBuy5,000.006.8334,150.00472,352.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120054440/0001209191-20-054440-index.htm
2020-06-03JOHN M. LEONARDPresident and CEOBuy5,000.006.8334,150.00472,352.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120034724/0001209191-20-034724-index.htm
2020-07-01JOHN M. LEONARDPresident and CEOBuy5,000.006.8334,150.00472,352.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120040251/0001209191-20-040251-index.htm
2020-08-06JOHN M. LEONARDPresident and CEOBuy5,000.006.8334,150.00472,352.00https://www.sec.gov/Archives/edgar/data/1652130/000089924320021784/0000899243-20-021784-index.htm
2020-09-01JOHN M. LEONARDPresident and CEOBuy5,000.006.8334,150.00472,352.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120049379/0001209191-20-049379-index.htm
2020-11-04JOHN M LEONARDPresident and CEOBuy50,000.006.83341,500.00517,352.00https://www.sec.gov/Archives/edgar/data/1652130/000120919120057297/0001209191-20-057297-index.htm
2019-03-06ANDREW SCHIERMEIEREVP, Dev and Corp StrategyBuy4,250.0015.5065,875.007,500.00https://www.sec.gov/Archives/edgar/data/1652130/000120919119018817/0001209191-19-018817-index.htm